ENGINEERING DE NOVO ANTITUMOR IMMUNITY USING PATIENT-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED T CELLS. DEVELOPMENT OF A NEW CLASS OF CARS EXPLOITING THE BROAD AND SELECTIVE GBM BINDING PROPERTIES OF THE SCORPION TOXIN PEPTIDE CHLOROTOXIN (CTX) AND EVALUATE THE POTENTIAL OF A CTX-CAR TO LIMIT GBM ANTIGEN ESCAPE.